Akèy › Neuroblastom › Ohio
Etid klinik pou Neuroblastom nan Ohio
8 etid pou Neuroblastom ap chèche patisipan nan sit nan Ohio.
Vil nan Ohio
Tèks ofisyèl etid la (Anglè)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- ak 4 plis
Ap rekriteFaz 3
Jiska laj 30 · Tout sèks · Mizajou Oct 2, 2026 · NCT06172296Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- Cleveland Clinic Foundation, Cleveland
- ak 3 plis
Ap rekriteFaz 3
365 Days – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma
- Cincinnati Children's Hospital Medical Center, Cincinnati
Ap rekriteFaz 2
Laj 1 a 39 · Tout sèks · Mizajou Aug 24, 2026 · NCT07635056SPEARHEAD-3 Pediatric Study
- Cincinnati Children's Hospital Medical Center, Cincinnati
Ap rekriteFaz 1/2
Laj 2 a 21 · Tout sèks · Mizajou Aug 11, 2026 · NCT05642455NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
Ap rekriteFaz 2
Laj 1 a 31 · Tout sèks · Mizajou Jul 20, 2026 · NCT06450041Neuroblastoma Biology Study
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
Ap rekriteEtid obsèvasyon
31 Days – 99 Years · Tout sèks · Mizajou Mar 23, 2026 · NCT01587300A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Nationwide Children's Hospital, Columbus
Ap rekriteFaz 2
18 Months – 40 Years · Tout sèks · Mizajou Aug 12, 2025 · NCT05135975Sous ClinicalTrials.gov, done yo ranmase Oct 3, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.